News Conference News ACC 2025 RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI Michael O'Riordan April 02, 2025
News Conference News ACC 2022 ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI Todd Neale April 05, 2022
News Conference News ACC 2021 ACTION: Full-Dose Rivaroxaban Doesn’t Help in Hospitalized COVID-19 Todd Neale May 17, 2021
News Conference News ACC 2021 Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC Michael O'Riordan May 17, 2021
News Conference News ACC 2020 Caravaggio Backs Apixaban for Prevention of VTE Recurrence in Cancer Patients L.A. McKeown April 01, 2020
News Conference News ACC 2020 PRONOMOS: Rivaroxaban Beats Enoxaparin for Preventing VTE After Orthopedic Surgery Yael L. Maxwell March 31, 2020
News Conference News ACC 2020 Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach Todd Neale March 28, 2020
News Conference News ACC 2019 REDUCE-IT Subanalysis: Icosapent Ethyl Reduces Total and Recurrent CV Events Yael L. Maxwell March 22, 2019
Presentation ACC 2018 Comparison of Effectiveness, Safety, and The Net Clinical Outcome Between Different Direct Oral Anticoagulants Presenter: Steve Deitelzweig March 12, 2018
News Conference News ACC 2018 ACC 2018, Day Three: Gout, Hypertension, Diabetes, PFO Closure, DAPT, NOAC Reversal, and More Shelley Wood March 12, 2018
News Conference News ACC 2017 Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery Michael O'Riordan March 19, 2017
News Conference News ACC 2017 Replacing Aspirin With Low-Dose Rivaroxaban for Post-ACS Therapy Appears Safe Todd Neale March 18, 2017
News Conference News ACC 2017 Rivaroxaban Bests Aspirin for Preventing Recurrence of VTE: EINSTEIN CHOICE L.A. McKeown March 18, 2017
News Conference News ACC 2017 ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More Shelley Wood March 10, 2017